Member Info for OilMan1984

https://www.bioworld.com/articles/499072-as-who-findings-disappoint-covid-19-developers-stand-in-solidarity

Turku, Finland-based Faron Pharmaceuticals Oy is not giving up on interferon beta-1a in COVID-19, delivered by a different route than in Solidarity. Findings from the WHO experiment “support our long-held view that interferon beta-1a is likely to be ineffective when given subcutaneously, CEO Markku Jalkanen said. “The science behind [Faron’s] Traumakine and its potential to prevent multi-organ failure through the upregulation of the key endothelial enzyme CD73 is compelling, and we continue to believe that an intravenous [I.V.] formulation of interferon beta-1a is what patients need to strengthen the body's own interferon beta signaling,” and thereby “provide optimal exposure to the lung vasculature.” Specifically, the I.V. approach achieves more than 150 times higher peak concentration there.

Pharmamar making strides

A global trial at more than 200 sites in 19 countries is testing Traumakine and other treatments for community-acquired pneumonia, including in COVID-19 patients. Faron is also supporting a potential phase II/III U.S. effort to probe the potential of the drug against COVID-19. To be conducted at Harvard Medical School’s Beth Israel Deaconess Medical Center, the effort awaits finalized funding arrangements and regulatory approval. It will focus on intensive-care patients with acute respiratory distress syndrome caused by viral infections that include COVID-19 and influenza. Traumakine will be tested against placebo and dexamethasone.

In hindsight was a small Bio Tech firm from Finland ever going to allowed to save the day during a WHO flagship trial? No. Big Pharma have pushed for interferon being administered via the subcutaneous method. Why, because this isn’t patent protected. I wonder whether Faron have been approached by any major Pharma over the last few months? Maybe so , but clearly the deal hasn’t been good enough for Markku to sign on the dotted line!

I believe that interferon beta will work in some format, previous research & results prove this. The evidence now points to IV method being one of the only solutions for patients with ARDS. Yes, the SNG inhaled version could work patients in the early stages of covid! But we need some positive results to really get things going here.

Frustrating day today but let’s not lose any hope.

It’s been an informative chat board today. Have a good weekend.

Another £2.5k added. That’s £7.5k! Buying no more, i promise!!

Anyway, another £5k added into the pot!

Our I.V method is patent protected. Big Pharma have pushed the subcutaneous method and its not working, surely they'll come knocking on Farons door to partner up?

Looks like all our eggs are in the REMAP-CAP basket until HIBISCUS gets moving.

I’ve emailed investor relations. Let’s see if we get a response!

22% down on the Naz & Lago have started buying shares over there!!!!!

News imminent!!!

Acute respiratory distress syndrome (ARDS) Pipeline Market Global Insight 2020 Key Players and Products Analysis Report.

Key Players- Faron Pharmaceuticals Ltd
Key Products - Interferon Beta
Acute respiratory distress syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as - Intravenous

https://www.openpr.com/news/2160696/acute-respiratory-distress-syndrome-ards-pipeline-market

Remember this article: Ok, the author may be slightly biased.
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03048-5

Was the news leaked as part of this arm The Solidarity trial based on SC administration? This is the key info' needed? Maybe send an email to investor relations today................The article above clearly explains that SC administration produces significantly lower drug concentrations and incomplete biovailibility compared to IV administration.

Also, Faron have I.V method patent protected. If, and if, the I.V method is successful then we could be lined up for one hell of a partnering deal. Don't forget a manufacturing agreement was put in place for Traumakine not that long ago.

Lets hope Interferon Beta I.V administered as a monotherapy as part of REMA-CAP delivers promising results!

Surely the 'leak' from the Solidarity trial would warrant an RNS if its the I.V method? If there's no RNS at 7am then does this mean the leak is linked to the subcutaneous method?

I wouldn't of expected the BOD would of released the 'Grant of Option's at £3.44 a share if they were expecting poor results from both Solidarity & REMAP-CAP.

There's been no mass sell off over the last few weeks. In fact appetite over on the naz over the last few weeks has been most healthy. Regardless, lets see how the market reacts to the news at 8am.

https://mobile.twitter.com/Dr_Kopite/status/1316954367707197440/photo/1

https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1

https://www.who.int/news/item/15-10-2020-solidarity-therapeutics-trial-produces-conclusive-evidence-on-the-effectiveness-of-repurposed-drugs-for-covid-19-in-record-time

TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that the Company's board has confirmed the grant of a total of 690,333 options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019. The Options have been allocated under the Share Option Plan 2019 and are exercisable between 23 July 2021 and 23 July 2025 at an exercise price of €3.80 per share (£3.44), vesting 25% per annum over a period of four years. The exercise price is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM over a period of 90 days preceding the allocation date of 23 July 2020. The amended terms of the Share Option Plan 2019 are as attached to the notice of the Company's 2020 annual general meeting, available on the Company's website, results of which were announced on 18 May 2020.



The granted 690,333 Options entitle the option holders to subscribe for a total of 690,333 new ordinary shares in the Company, if exercised in full, and represent 1.5% of the fully-diluted ordinary share capital of the Company.



Included in the number of Options granted are the following Options which were issued to directors, other persons discharging managerial responsibilities ("PDMRs"), Scientific Advisory Board ("SAB") persons closely associated with them ("PCAs") and Company personnel:



Director

Options granted

Armstrong Frank

60,000

Brown Gregory

30,000

Jalkanen Markku

120,000

Manner Matti

30,000

Poulos John

30,000

Zambeletti Leopoldo

30,000

Total directors

300,000





Other PDMR



Honkasalo Pessi

12,000

Hänninen Toni

43,333

Jalkanen Juho

32,500

Karvonen Matti

32,500

Lahtinen Maria

21,000

Mandelin Jami

21,000

Wichmann Yrjö

12,000





Total other PDMRs

174,333





Scientific Advisory Board



Jalkanen Sirpa*

10,000

Knowles Jonathan

10,000

Curiel Tyler

10,000

Total SAB

30,000

Long, is English your first language!!

Nice to see LAGO hoovering up some shares for our Finnish friends.

Fantastic research Sax. Much Appreciated.

Hi Whirlaw, whilst agreeing with most of your points, prior to the RRE Marathon Takeover being announced in 2019 volume increased quite significantly. When RRE relisted at £18.50 i decided to jump ship, then buy back in April this year at £6.09 selling once again at £18.40. I believe the frenzy here a couple of months ago was the week after RRE deal was announced with profit takers there happy to plunge here was news expected H1. Anyway, were now into Q4 witj no news yet. Am i concerned - NO. Ive got a decent holding holding here of 30k shares. When funds allow ill certainly being topping up as in my opinion this is only going one way!

Faron have shared the article i posted yesterday on here via their LinkedIn page. This goes to show the importance of Interferons treating Respiratory related illnesses. News due Q4!

The importance of early Interferon Beta in coronavirus; Published in NEJM
This recently published paper in NEJM by Arabi et al. concerning the MIRACLE trial, has shown that Interferon beta together with lopinavir and ritonavir has a significant mortality benefit in MERS. In this placebo controlled RCT mortality in the active arm was 28% while in the placebo arm, it was 44%. The benefit comes from early intervention. There was an 81% reduction in mortality if patient treatment started within seven days of symptom onset

https://www.nejm.org/doi/full/10.1056/NEJMoa2015294

https://www.linkedin.com/company/faron/

https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/bp-could-wait-for-oil-price-recovery-before-putting-uk-assets-back-on-market-60621366